| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 28.03 mm | 28.03 mm | 28.03 mm | 28.03 mm | 28.03 mm | 28.03 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 3.45 mm | 3.41 mm | 2.42 mm | 3.18 mm |
| Cash used (since last report) | n/a | n/a | 17.46 mm | 17.26 mm | 12.28 mm | 16.13 mm |
| Cash remaining | n/a | n/a | 10.57 mm | 10.77 mm | 15.75 mm | 11.90 mm |
| Runway (months of cash) | n/a | n/a | 3.1 | 3.2 | 6.5 | 3.7 |
| 13F holders | Current |
|---|---|
| Total holders | 13 |
| Opened positions | 5 |
| Closed positions | 3 |
| Increased positions | 2 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 2.25 bn |
| Total shares | 6.71 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GKCC | 5.59 mm | $25.05 mm |
| Clal Biotechnology Industries | 481.73 k | $4.17 mm |
| Vanguard | 245.26 k | $1.23 bn |
| Vifor | 199.56 k | $2.19 mm |
| Geode Capital Management | 71.57 k | $360.06 mm |
| CM Management | 50.00 k | $251.50 mm |
| NTRS Northern Trust | 30.77 k | $154.77 mm |
| BlackRock | 19.69 k | $99.06 mm |
| Meyer Handelman | 13.90 k | $69.91 mm |
| CIBC Private Wealth | 7.00 k | $42.56 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Feb 25 | Robert Connelly | Stock Option Common Stock | Grant | Acquire A | No | No | 8.92 | 121,600 | 1.08 mm | 121,600 |
| 3 Feb 25 | Peter DeMuth | Stock Option Common Stock | Grant | Acquire A | No | No | 8.92 | 44,400 | 396.05 k | 44,400 |
| 3 Feb 25 | Christopher Haqq | Stock Option Common Stock | Grant | Acquire A | No | No | 8.92 | 44,000 | 392.48 k | 44,000 |
| 16 Dec 24 | Peter DeMuth | Common Stock | Option exercise | Acquire M | No | No | 4.41 | 381 | 1.68 k | 381 |
| 16 Dec 24 | Peter DeMuth | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.41 | 381 | 1.68 k | 0 |
| 26 Nov 24 | Venkatesan Jay | Common Stock | Acquire X | No | No | 0.01 | 50,000 | 500.00 | 179,581 | |
| 26 Nov 24 | Venkatesan Jay | Warrant to Purchase Common Stock Common Stock | Dispose X | No | No | 0.01 | 50,000 | 500.00 | 0 |
